Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trilomer-HER2 conjugate
- Development stage
- Preclinical
- Lead developer
- Trilo Therapeutics
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
01
Overview
Trilomer-HER2 conjugate is a preclinical-stage peptide-drug conjugate (PDC) developed by Trilo Therapeutics for the treatment of HER2-expressing cancers. It utilizes the company's proprietary Trilomer® platform, which consists of mirror-image D-amino acid cyclic peptides. These D-peptides are designed to be highly stable, protease-resistant, and non-immunogenic. The conjugate acts in an "ADC-like" manner, where the bivalent or biparatopic D-peptide binder specifically targets the Human Epidermal Growth Factor Receptor 2 (HER2) on cancer cells to deliver a conjugated cytotoxic or radionuclide payload, leading to targeted cell death.
- Other names
- Trilomer-HER2 peptide-drug conjugateTrilomer-HER-2 peptide-drug conjugateTrilomer-HER 2 peptide-drug conjugate
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on Trilomer-HER2 conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trilomer-HER2 conjugate.